The field of neuronal autoantibody associated diseases of the central nervous system has expanded dramatically in the last few years. The range of identified neuronal and glial antibody targets has led to the accurate classification of a number of syndromes which each associate with characteristic clinical features. These diseases are especially important due to their frequent response to immunotherapies. Antibodies against the N-methyl, D-aspartate receptor (NMDAR) and leucine-rich glioma inactivated 1 (LGI1) are the commonest autoantibodies known in patients with autoimmune forms of encephalitis. Patients with NMDAR-antibodies often present with psychiatric symptoms and a movement disorder, whereas patients with LGI1-antibodies have frequent seizures and prominent amnesia. In contrast, aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies are found in patients with inflammation of the spine and optic nerves. The antigenic-specificities appear to determine the associated clinical syndromes, hence the detection of these antibodies informs clinical practice and the biology of these diseases. Indeed, the mechanisms of antibody action are being intensively studied in vitro and in vivo. Overall, these studies confirm the pathogenic potential of the antibodies, and suggest antigen internalisation and complement fixation are the two dominant mechanisms of pathogenicity, and that their relative contributions vary between conditions. In addition to discussing the antigenic targets, the associated clinical features and mechanisms of antibodies, we review the current and future immunotherapy strategies which aim to optimise patient outcomes.
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Abbreviations: NSAb, neuroglial surface antibodies; NMDAR, N-methyl, D-aspartate receptor; GABARA A/B , g-aminobutyric acid receptor A or B; LGI1, leucine-rich glioma inactivated 1; CASPR2, contactin-associated protein-like 2; AQP4, aquaporin 4; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic; DPPX, dipeptidyl-peptidase-like protein 6; GAD65, glutamic acid decarboxylase 65; AChR, acetyl-choline receptor; NMO, neuromyelitis optica; ON, optic neuritis; TM, transverse myelitis; LETM, longitudinally extensive transverse myelitis; NMOSD, NMO spectrum disorder; MS, Multiple Sclerosis; PRES, posterior reversible encephalopathy syndrome; OAPs, orthogonal array particles; EAAT2, excitatory amino acid transporter-2; FBDS, faciobrachial dystonic seizures; MoS, Morvan's syndrome; NMT, neuromyotonia; NMDAR-AbE, N-Methyl-DAspartate Receptor antibody encephalitis; SPS, stiff person syndrome; SPSD, stiff person spectrum disorder; PERM, progressive encephalomyelitis, rigidity and myoclonus; VGKC, voltage-gated potassium channels; LE, limbic encephalitis; SIADH, syndrome of inappropriate anti-diuretic hormone secretion; PSD-95, post-synaptic density protein 95; ADAM22/23, a disintegrin and metalloproteinase domain-containing protein 22/23; CSF, cerebrospinal fluid (CSF); MRI, magnetic resonance imaging; EEG, electroencephalogram; HSE, herpes simplex virus encephalitis; SCLC, small cell lung cancer; IVIG, intravenous immunoglobulin; mRS, modified rankin scale.
Introduction
Autoantibodies against a number of proteins have been associated with well-defined diseases of the CNS. Frequently, the antigens are ion channels, including the N-Methyl, D-aspartate receptor (NMDAR) and the g-aminobutyric acid A receptor (GABA A R). Other categories of molecules include ligand-gated receptors and cell adhesion molecules. Importantly, these antibodies target extracellular protein domains and have pathogenic potential as they can access their target at the neuroglial cell surface. Antibody pathogenicity is supported by emerging in vitro and in vivo models, and the responses of patients to immunotherapies (Armangue et al., 2014a; Irani et al., 2014a; Varley et al., 2014) . The diseases associated with these neuroglial surface antibodies (NSAbs) have markedly different characteristics to the classical tumour-related 'paraneoplastic' antibodies which target intracellular epitopes. The latter are likely epiphenomena in diseases driven primarily by Tcell mechanisms, and, accordingly, these conditions tend not respond well to immunotherapies (Hoftberger et al., 2015) .
In this review, we will describe the main NSAb targets with a focus on their function in health and disease, highlight the frequently distinctive associated clinical syndromes (Table 1) , and outline established and novel treatment strategies for these increasingly-recognised illnesses.
The most common NSAb targets

Aquaporin-4 (AQP4)
Neuromyelitis optica (NMO) is typically characterised by inflammation of the spinal cord and optic nerves. Its recognition as a distinct entity stemmed from the syndrome of simultaneous bilateral optic neuritis (ON) and transverse myelitis (TM) originally described by Devic and Gault in 1894: 'Devic's disease'. Historically, NMO was thought to be a severe form of multiple sclerosis (MS), but recognition of a specific CNS serum IgG-binding pattern and subsequent identification of the AQP4 water channel as the target for this antibody helped to distinctively delineate this condition (Lennon et al., 2005) .
Indeed, the AQP4-IgG has become an important diagnostic test for clinicians. The classical features of NMO are presentations of ON and TM which are different to those observed in MS. The ON is often bilateral and shows poorer recovery than ON seen in MS (Jarius et al., 2010) . The TM is usually longitudinally extensive (LETM; greater than three vertebral segments), and commonly affects both the grey and white matter, with corresponding motor and sensory features . The term NMO spectrum disorder (NMOSD) was more recently developed to describe the broader clinical phenotype associated with the AQP4-autoantibody. In addition to the features above, patients may present with a more limited phenotype, or with syndromes not recognised in the original diagnostic criteria. For example, brain lesions are now known to be common: periaqueductal lesions in the hypothalamus and dorsal brainstem can associate with unique syndromes, particularly the area postrema syndrome with intractable vomiting or hiccoughing (Iorio et al., 2013) . More extensive brain lesions involving the midbrain, cerebellum and cerebral white matter can occur, and posterior reversible encephalopathy syndrome (PRES)-like lesions have been described (Magana et al., 2009) . Recent reports raise the interesting possibility that NMOSD may extend beyond the CNS. AQP4 is expressed in skeletal muscle and rhabdomyolysis has been reported in association with NMO attacks (Suzuki et al., 2010) . In addition, retinal Mueller cells express AQP4 and retinal changes have been observed in patients with NMO (Green and Cree, 2009) .
AQP4 is the predominant water channel in the brain and spinal cord. It has polarized expression, and is concentrated on astrocytic end-feet at fluid-parenchymal interfaces, suggesting a role in brain water fluxes. In addition to skeletal muscle, it is also expressed in the stomach, lung, kidney, inner ear, retina and olfactory epithelium (Amiry-Moghaddam and Ottersen, 2003) . It is not well understood why many of these organs are clinically silent in NMO but this may relate to resistance against complement or AQP4 internalisation. AQP4 exists as two major isoforms: a long isoform M1, and a short isoform M23 (this Lu et al., 1996) . These isoforms tetramerise, and M23 further aggregates in the cell plasma membrane in supramolecular structures described as orthogonal array particles (OAPs) (Yang et al., 1996) .
An antibody-mediated pathogenesis for NMOSD is supported by a number of observations. First, AQP4 distribution in the normal CNS is prominent within the spinal cord, optic nerve and brainstem, consistent with the disease phenotype . Other areas also express AQP4, yet the brainstem expression is most dense within the floor of the fourth ventricle-which includes the area postrema (Popescu et al., 2011) . Second, pathology demonstrates striking AQP4 loss which associates with IgG and IgM deposition and complement activation . The IgG1-predominant AQP4-antibodies can initiate both complementdependent cytotoxicity and antibody-dependent cellular cytotoxicity (Hinson et al., 2007; Kalluri et al., 2010) . Complement activation appears to be a prominent pathological mechanism, and the tendency of AQP4 to form densely-clustered OAPs on astrocytes is likely to increase available divalent IgG-binding sites and hence complement binding potential (Duncan and Winter 1988) . Indeed, cells which express M1 AQP4, and are unable to form OAPs, resist complement activation (Phuan et al., 2012) . This is of clinical relevance as it suggests that established lesions with complement deposition are unlikely to show a major recovery with immunotherapies. Third, in vitro studies show rapid AQP4-IgG induced internalisation and degradation of AQP4 in transfected cells, and in astrocytes (Hinson et al., 2008) . M23 may be more resistant to this within OAPs. Fourth, AQP4-IgG binding is associated with loss of the excitatory amino acid transporter EAAT2, that complexes with AQP4. Excess extracellular glutamate, due to disruption of EAAT2 clearance, could contribute to excitotoxic cell death. AQP4-IgG does not appear to disrupt channel function or inhibit water permeability directly (Melamud et al., 2012) . CNS AQP4-IgG passive transfer animal models for NMO with direct intrathecal infusion successfully reproduce the disease features confirming pathogenicity . After peripheral infusions of AQP4-IgG, a 'second-hit', such as myelin immunisation or exogenous complement, are required to mimic aspects of the disease in experimental animals (Kinoshita et al., 2009; Ratelade et al., 2011) .
2.2. Leucine-rich glioma inactivated-1 (LGI1) and contactinassociated protein-like 2 (CASPR2) antibodies
The discovery of two other common NSAbs, against LGI1-and CASPR2, the associated deductive biochemistry used to determine these targets, and their clinical importance are described below. Limbic encephalitis (LE) (Thieben et al., 2004; Vincent et al., 2004) , some forms of epilepsy including faciobrachial dystonic seizures (FBDS; Fig. 1A ) (Irani et al., 2008 ), Morvan's syndrome (MoS) (Irani et al., 2012) , and neuromyotonia (NMT) (Shillito et al., 1995) were originally described in association with antibodies against voltage-gated potassium channels (VGKC). VGKC-antibodies were determined using a radioimmunoprecipitation assay from solubilised brain tissue. However, in 2010, clinical and biochemical studies revealed that the extracellular-domains of LGI1 and CASPR2, rather than the VGKC, were frequently targets of these antibodies from patients with LE, FBDS, MoS and NMT (Irani et al., 2010a; Klein et al., 2013; Lai et al., 2010) . In light of these findings, and to highlight the frequent co-immunoprecipitation of LGI1 or CASPR2 alongside radiolabelled VGKCs, the term VGKC-complex antibodies was introduced to describe this antigenic complex. However, these LGI1-and CASPR2-antibody positive patients accounted for almost all immunotherapy-responsive syndromes associated with VGKC-complex antibodies. Many of the remaining VGKC-antibody positive patients, without LGI1 or CASPR2-reactivities ("double-negative" reactivities), had more heterogeneous syndromes which were less clearly immunotherapyresponsive. Recently, it has been shown that these doublenegative autoantibodies were often directed against the intracellular aspects of VGKCs themselves, and some targeted the nonneuronal protein dendrotoxin (DTX): these are both unlikely to be pathogenic autoantibodies. Furthermore very rarely did doublenegative antibodies bind to the surface of live hippocampal neurons (Lang et al., 2017) . Therefore, as LGI1-and CASPR2-antibodies targeted the outside of cell surface proteins, were more clinically useful than VGKC-complex antibodies, and their direct determination showed greater sensitivity than VGKC-complex antibody determination Irani et al., 2013) , the terms LGI1-and CASPR2-antibodies are now preferentially used. These targets and the associated likely antibody pathogenicity is summarised in Fig. 1B .
LG11
Around 80% of patients with LGI1-antibodies initially present with a variety of focal seizures, in around half these are the pathognomonic FBDS (Fig. 1A) . FBDS are stereotyped, brief (<3s), posturing movements of the hand and ipsilateral hemi-face characterised by their strikingly high frequency (median 50/day) . FBDS precede the development of the more severe LE phenotype in around two-thirds of cases (Irani et al., , 2013 van Sonderen et al., 2016) . Patients can also initially present with other seizure semiologies, such as medial temporal lobe seizures, including bradycardia (Naasan et al., 2014) , and autonomic features such as piloerection (Rocamora et al., 2014) , and more rarely with Morvan's syndrome Irani et al., 2010a; Lai et al., 2010; van Sonderen et al., 2016) .
Typically, patients with FBDS or other forms of seizures, progress over time to an established LE. At this point, the condition is characterised by subacute onset amnesia with ongoing seizures and psychiatric disturbances (Irani et al., 2010a; Lai et al., 2010) . In conjunction, there is often hippocampal high signal on T2-weighted magnetic resonance imaging (MRI) (Fig. 1C ) and serum hyponatraemia, most often due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) (Irani et al., 2010a; Lai et al., 2010) . Some variation has been reported in presenting phenotype, with cognitive impairment also reported at disease onset (Irani et al., , 2013 Navarro et al., 2016) . In the longer term, patients often develop hippocampal atrophy and a fixed memory deficit which associate with long-term disability (Butler et al., 2014; Malter et al., 2014) . Other residual cognitive deficits are also recognised .
LGI1 is a 64 kDa, secreted protein expressed mainly in the hippocampus and neocortex (Irani et al., 2010a) . It forms a transsynaptic complex with pre-synaptic a disintegrin and metalloproteinase domain-containing protein 23 (ADAM23), and post-synaptic ADAM22. Studies have shown that LGI1 may interact with post-synaptic a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptors, post-synaptic density protein 95 (PSD95), and with presynaptic Shaker Kv1-potassium channels. The relative contributions of these proteins to LGI1-antibody pathogenicity has not been systematically examined. However, it is known that murine mutations of LGI1 disrupt the formation of this complex and specifically abrogate AMPAmediated synaptic signalling (Fukata et al., 2010) . Indeed, in vitro and in vivo work showed that LGI1-antibodies inhibited LGI1 binding to ADAM22 and 23. This caused a reversible reduction of synaptic AMPA receptors and a loss of function of inhibitory interneurons, with consequent excess neuronal-network excitation and seizures (Ohkawa et al., 2013) . Therefore, although LGI1 is not a channel itself, pathology affecting LGI1 can lead to secondary channel dysfunction. Further to this, LGI1-antibodies in human disease are predominantly of the IgG4 subclass Irani et al., 2012) and therefore the majority do not fix complement. This is intriguing as despite the demonstration of complement deposition in post-mortem tissue (Bien et al., 2012) , significant symptomatology can occur without cerebrospinal fluid (CSF) or MRI evidence of inflammation Irani et al., 2011 Irani et al., , 2013 van Sonderen et al., 2016) . The relative roles of inflammatory and non-inflammatory of LGI1-antibodies require further study. 
CASPR2
Patients with antibodies against CASPR2 often show a strong male predominance, and age of onset in later life (Irani et al., 2010a (Irani et al., , 2012 Klein et al., 2013; Lancaster et al., 2011) . Clinical syndromes tend to have prominent NMT. NMT is a syndrome of peripheral nerve hyperexcitability with cramps, stiffness and fasciculations (Shillito et al., 1995) . Patients with CASPR2-antibodies can present with NMT alone, a purely CNS-based LE, or features of both in the form of MoS. In addition to NMT and an encephalopathy, patients with MoS often show additional circadian cycle reversal and multiorgan autonomic dysfunction (Klein et al., 2013) . LE with CASPR2-antibodies can also often be accompanied by autonomic features, pain or cerebellar symptoms, although these are typically mild compared to the severity of the features seen in patients with MoS. More rarely, CASPR2-antibodies can occur in patients who present with an isolated epilepsy or cognitive impairment (Irani et al., 2010a (Irani et al., , 2012 Lancaster et al., 2011) . Thymomas are present in around 40% of patients with MoS (Vincent and Irani, 2010) and in around 10% with other presentations (Lancaster et al., 2011) . Probably partly driven by this tumour association, it is possible to have dual NSAb positivity with CASPR2 and acetyl-choline receptor (AChR)-antibodies (Iwasaki et al., 1990) or CASPR2-and LGI1-antibodies (Irani et al., 2012) .
CASPR2 is a 148 kDa protein with a large extracellular domain of over 1200 amino acids. It is predominantly expressed within the juxtaparanodal region of myelinated axons in the brain and peripheral nervous system (Poliak et al., 2003) . It is a neuronal cell adhesion molecule which is crucial for clustering of Kv1.1 and Kv1.2 at the juxtaparanode (Gu and Gu, 2011) , though its role in synaptic function remains less well understood. CASPR2 is also expressed at lower levels in the parathyroid glands, with evidence of RNA expression in the adrenal and prostate glands, as well as the rectum and ovaries (Uhlen et al., 2015) . Mutations in the gene encoding CASPR2 are linked to autistic spectrum disorders, seizures, attention-deficit hyperactivity disorder, and schizophrenia (Rodenas-Cuadrado et al., 2014) . Antibodies to CASPR2 are of the IgG4, and less so IgG1, subclass (Irani et al., 2012) and target multiple epitopes predominantly in the N-terminus of the antigen (Olsen et al., 2015) .
N-Methyl-D-Aspartate receptor
Although its precise incidence is unknown, N-Methyl-D-Aspartate Receptor antibody encephalitis (NMDAR-AbE) appears to be the most common antibody-mediated encephalopathy (Kim et al., 2014) . The antigenic target was originally discovered in 2007, in a cohort of 12 women with teratomas (Dalmau et al., 2007) . Patient sera and CSFs bound distinctively to the neuropil of the hippocampus and to the cell surface of hippocampal neuronal cultures, and autoantibodies were identified as targeting the NMDAR following candidate antigen testing.
NMDAR-AbE predominantly affects children and young woman (median age 21 [range 1e95], 81% female) (Titulaer et al., 2013) . Whilst the original description was of an exclusively paraneoplastic disease associated with a teratoma, usually ovarian, case-series now show tumour rates of 21e38% (Irani et al., 2010b; Titulaer et al., 2013) , which are less common in children and men. Yet, the frequent association with ovarian teratomas is important with regards to immunopathogenesis. Ovarian teratomas express neural tissue including the NMDAR (both NR1 and NR2 subunits) (Dalmau et al., 2007; Tabata et al., 2014) and are the likely source of the original immunisation. Lymphocytic inflammatory infiltrates (particularly B cells) in all teratomas from patients with encephalitis (Dabner et al., 2012) , and less commonly in those without encephalitis, suggest a germinal-centre like structure which primes and activates the antibody-secreting cells.
The NMDAR-AbE associated syndrome is usually highlycharacteristic with a stereotyped evolution. Disease onset is with an acute neuropsychiatric presentation including psychosis, seizures and cognitive impairment, appearing over a few days. This often follows a prodrome of fever, headache, or abdominal pain. Later, features develop after 10e20 days and include a distinct movement disorder (Kleinig et al., 2008) , dysautonomia and coma (Irani et al., 2010b) . The clinical course is very often severe, with 75% of patients requiring intensive care unit admission, and an associated mortality of 7% (Titulaer et al., 2013) .
The movement disorder of NMDAR-AbE encephalitis is particularly striking and most frequently described using terms including catatonia, chorea, dystonia, akathisia, and orofacial dyskinesias (Baizabal-Carvallo et al., 2013; Duan et al., 2016; Mohammad et al., 2014a) . Kleinig et al. reviewed the movement disorder closely in four cases with prominent and complex orobulbar movements ( Fig. 2A) , oculomotor movements (rhythmic and tonic), opisthotonus, rigidity, dystonic posturing, truncal spasms and catalepsy. The complex pattern of ocular, bulbar, trunk and limb movements has been hypothesized as implicating brainstem pattern generators. These are under tonic GABAergic inhibitory control, such that diffuse supratentorial NMDAR-expressing neuron modulation could release descending inhibition control (Kleinig et al., 2008) .
CSF analysis demonstrates lymphocytic pleocytosis in around 80% of patients (Dalmau et al., 2008; Irani et al., 2010b; Titulaer et al., 2013) , consistent with an encephalitis. Elevated IgG index and CSF-specific oligoclonal bands (Dalmau et al., 2008; Irani et al., 2010b) are supportive of intrathecal antibody synthesis, with oligoclonal bands becoming positive later in the disease. In contrast to many other causes of encephalitis, MRI is often normal, or only shows non-specific changes in around 30% of patients (Titulaer et al., 2013) . Electroencephalogram (EEG) suggests a diffuse encephalopathy, and is abnormal in 90%, with background slowing (Titulaer et al., 2013) . A distinctive EEG pattern, extreme delta brush (Schmitt et al., 2012) , has been described in up to 30% of NMDAReAbE encephalitis patients requiring ITU care (example in Fig. 2B ). This is characterised by diffuse delta rhythms of 1e3 Hz, with superimposed rhythmic bursts of faster beta activity. Whilst the specificity of this finding is unclear, NMDAR hypofunction has been postulated as a major contributor.
NMDAR-AbE is now well-recognised in the context of herpes simplex virus encephalitis (HSE). Initially, a proportion of patients with HSE were found to have NMDAR-antibodies in serum and CSF but the clinical significance of these antibodies, and their time course were variable (Pruss et al., 2012) . Relapsing choreoathetoid and encephalopathic symptoms in children post-HSE have long been recognised, but were not attributable to direct viral cytotoxicity (Gascon et al., 1993) . The discovery that many of these children had de novo generation of NMDAR-antibodies during this relapsing choreoathetoid-encephalopathy, suggested the relapse was mediated by NMDAR-antibodies (Armangue et al., 2014b; Hacohen et al., 2014; Mohammad et al., 2014b) . Indeed, immunotherapy e rather than antiviral agents -appear beneficial in this context. More recently, it has become clear that these antibodies do not arise solely during such relapses, but can also be seen as part of the ongoing neuropsychiatric sequelae of HSE in adults and children (Westman et al., 2016) , taking this field 'full-circle' back to the original description of persistent NMDAR-antibodies in adult patients with HSVE (Pruss et al., 2012) .
NMDAR-antibodies may be an explanation for another historical neurological syndrome. Encephalitis Lethargica (EL) is characterised by a sleep disorder, extrapyramidal movement disorder (predominantly parkinsonism), and neuropsychiatric symptoms. An autoimmune cause has been proposed partly because patient serum IgG stained mammalian brain sections (Dale et al., 2004) . Indeed, NMDAR-antibodies have been detected in 10 of 20 paediatric patients with a clinical diagnosis of EL (Dale et al., 2009 ). The 10 patients with NMDAR-antibodies tended to have a more dramatic and dyskinetic movement disorder including chorea, dystonia, hemiballismus and oculogyric crisis, whilst seronegative patients presented more commonly with the parkinsonian form of EL.
NMDARs are ligand-gated ion channels, crucial in the regulation of CNS synaptic excitation and plasticity. NMDARs are a 'dimer of dimers', comprising two of the obligate NR1 subunits, with two NR2 (A e D) subunits. Glutamate and glycine binding are both required for ion channel opening which results in influx of cations including Ca 2þ , and downstream activation of signal transduction cascades (Lau and Zukin, 2007) . The NR1 subunit binds glycine, and the NR2 subunit binds glutamate. NMDARs are located on neurons in the hippocampus, cerebellum and cortex, and are composed of NR1 -NR2A/2B/2C/2D heteromers (Wenthold et al., 2003) . Autoantibodies in the NMDAR-antibody associated encephalitis target the extracellular amino-terminal domain of the NR1 subunit of the NMDAR (Dalmau et al., 2008; Kreye et al., 2016) . Patient sera and CSF binding co-localise with commercial antibody staining (Moscato et al., 2014) . In vitro studies have shown that patient sera and CSF lead to reductions of NMDAR cluster density, and are associated with impaired glutamatergic transmission (Kreye et al., 2016) . This effect is largely reversible upon antibody removal (Dalmau et al., 2008; Hughes et al., 2010; Kreye et al., 2016) . Perhaps surprisingly, this receptor internalisation appears to be the major mechanism in patients. Indeed, NMDAR-antibodies are predominantly of the complement-fixing IgG1 subclass (Irani et al., 2010b) and while patient brain tissue demonstrates IgG deposits, there is a paucity of complement deposition. The B cells and plasma cells present in perivascular regions and interstitial spaces, may provide the local source of antibody production (Bien et al., 2012; Martinez-Hernandez et al., 2011; Tüzün et al., 2009) .
Accumulating data are strongly supportive of a direct pathogenic effect of patient IgG. In vivo passive transfer of patient CSF by continuous intraventricular infusion has been shown to cause progressive memory and behavioural deficits in mice (Planagum a et al., 2015) , with an associated reduction in NMDAR hippocampal clusters. Inflammatory infiltrates, neuronal apoptosis and complement deposition were not detected, suggesting noninflammatory NMDAR hypofunction generated the phenotype, although this phenotype is rather different to that observed in humans with NMDAR-AbE. In addition, epileptogenicity of NMDARantibodies has been demonstrated in mice (Wright et al., 2015) . Human in vivo pathogenicity is supported by maternal to foetal transmission of NMDAR-antibodies resulting in a transient foetal encephalitic syndrome (Hilderink et al., 2015) .
The reduction of NMDAR cluster density appears to be due to two related but distinct mechanisms: internalisation and lateral dispersion. While extrasynaptic NMDARs are cross-linked by autoantibodies and endocytosed, antibody binding to synaptic NMDAR can cause lateral dispersion of the receptors (Fig. 2C) . The synaptic effect may be due to disruption of the Ephrin-B2-NMDAR complex, as NMDAR synaptic content is regulated by the expression of Ephrin-B2 (Mikasova et al., 2012; Nolt et al., 2011) . Indeed, Ephrin-B2 can antagonize this effect and, in mice, co-infusion of Ephrin-B2 alongside patient CSF IgG prevented cognitive and psychiatric symptoms. IgG binding to brain was not altered, but NMDAR cluster density reduction was largely prevented (Planagum a et al., 2016) .
In NMOSD, autoantibody-mediated pathology is primarily inflammatory. However, with NMDAR-AbE, NMDAR hypofunction due to antibody mediated receptor internalisation and dispersion provides a likelier explanation for the clinical features and frequent reversibility of this disease. Experiences with the NMDARantagonists ketamine and phenocyclidine (PCP) support this mechanism, as intoxication with these substances is associated with similar clinical features, including a movement disorder with facial involvement, agitation, hallucinations, delusions and autonomic dysfunction (Curran and Morgan, 2000; Marco and Joshi, 1992; McCarron et al., 1981) .
g-Aminobutyric acid A receptor (GABA A R) and g-Aminobutyric acid B receptor (GABA B R)
Antibodies to the GABA B R were first described in association with a LE that showed early, pronounced seizures and occasional status epilepticus . Other GABA B R-antibody associated syndromes have included cerebellar ataxia, opsoclonusmyoclonus, and brainstem involvement (Boronat et al., 2011; Dogan Onugoren et al., 2015; Kim et al., 2014; Lancaster et al., 2010; Qiao et al., 2016) . Affected patients are typically in their later life and there is a strong association with small cell lung cancer (SCLC) as reflected by the 3% seroprevalance of GABA B R-antibodies in patients with SCLC (Gozzard et al., 2015) .
More recently, antibodies to the GABA A R have been described in paediatric and adult patients with an encephalitis (Petit-Pedrol et al., 2014) . Serum antibodies against this protein are also described in a wider variety of neurological syndromes including patients with catatonia and seizures (Pettingill et al., 2015) . The antibody epitopes or subclasses may differ between various patient groups, and relative antigenicity of various GABA A a-, b-and gsubunits and the relative roles of CSF and serum antibodies are subjects for future studies.
GABARs are the major inhibitory receptors in the central nervous system. GABA A Rs and GABA C Rs are ionotropic ion channels, allowing flux of chloride ions and fast synaptic inhibition. GABA B Rs are G-protein coupled receptors which modulate slow presynaptic inhibition via second messenger systems (Ulrich and Bettler, 2007) . GABA B Rs are expressed in both the CNS, predominantly in the cortex, cerebellum, thalamus and less in the hippocampus, as well as the peripheral nervous system, in autonomic ganglia and visceral tissue (Benarroch, 2012) . They are heterodimers comprising the GABA B R subunits 1 and 2, with GABA B1 subunits containing the ligand binding domain (Pagano et al., 2001) . GABA B1 R knock-out mice die prematurely, with a phenotype of frequent seizures, cognitive impairment, hyperalgesia and hyperlocomotor activity . Furthermore, GABA B1 R polymorphisms have been associated with temporal lobe epilepsy (Xi et al., 2011) , schizophrenia (Zai et al., 2005b) and obsessive compulsive disorder (Zai et al., 2005a) . The overlap of the genetic and autoantibodyassociated phenotypes remains intriguing.
Antibodies associated with the encephalitis are predominantly of the IgG1 subclass , but, rather than fix complement or internalise the protein, antibodies to GABA B Rs may inhibit the channel function. Other reports suggest a key role for CD8 cytotoxic T cells in the pathology of this disorder, albeit in small numbers . This fits with the relatively high prevalence of MRI and CSF abnormalities and the frequent association with other antibodies directed against intracellular antigens.
Glutamic acid decarboxylase 65 (GAD65) and the glycine receptor
Low levels of GAD65-antibodies are present in association with type 1 diabetes mellitus. At much higher levels, GAD65-antibodies are associated with stiff person syndrome (SPS), cerebellitis, epilepsy, and LE (Saiz et al., 2008) . The patients with SPS typically present after years with axial and limb stiffness, spasms, plus auditory and tactile startle. They respond modestly to intravenous immunoglobulin (IVIG) and other immunosuppressive agents. The patients with LE often show a poor response to immunotherapy, and typically have an indolent chronic disease course, with relative resistance to anti-epileptic drugs (Malter et al., 2010 (Malter et al., , 2015 Martinez-Hernandez et al., 2016) . This, in combination with the fact that GAD65 is an intracellular antigen, has led to scepticism over the potential pathogenicity of GAD65-antibodies. Despite the fact that aspects of SPS can be reproduced in rodents by infusion of IgG from serum and CSF of GAD65-antibody positive SPS patients (Manto et al., 2007) , it remains challenging to explain the varied phenotypes associated with one autoantibody. One possibility is that the intracellular perisynaptic antigens are exposed to the autoantibodies within the synaptic cleft. This antigenic 'moonlighting' would offer transient opportunities for the antibodies to access the intracellular compartment (Irani, 2016) . An alternative explanation is that each syndrome has varying accompanying NSAb-reactivities which confer the clinical specificity (Chang et al., 2013) . One such established reactivity is the glycine receptor.
Antibodies to the glycine a1 receptor have been described in association with a rare disease phenotype: progressive encephalomyelitis, rigidity and myoclonus (PERM) (Carvajal-Gonzalez et al., 2014; Hutchinson et al., 2008; Iizuka et al., 2012; Turner et al., 2011) . PERM is considered to be a severe stiff person syndrome spectrum disorder (SPSD), with brainstem and/or myelopathic features plus rigidity, hyperekplexia and autonomic disturbance. When compared to patients with classical SPS and GAD65 antibodies, patients with glycine antibodies and PERM have a more severe disease course, with a higher median peak modified rankin scale (mRS), but can be more responsive to immunotherapy, and the responders have a greater improvement at follow-up .
Glycine receptors are ligand-gated anion channels which mediate fast inhibitory neurotransmission in the brain and spinal cord. They are pentameric, arranged concentrically around a central pore (Kuhse et al., 1995) . They are agonised by glycine, taurine or alanine, leading to selective flux of chloride or bicarbonate down the electrochemical gradient, with consequent neuronal hyperpolarisation (Zeilhofer et al., 2012) . Functionally, glycine receptors are important for muscle tone, co-ordination, respiratory rhythm and sensory processing. Accordingly, mutations in glycine receptors lead to hyperekplexia, neonatal hypertonia, developmental delay and apnoea (Harvey et al., 2008; Thomas et al., 2013) .
Glycine receptor antibodies are predominantly of the IgG1 subclass, and reduce glycine receptor expression at the cell surface, with targeting of the receptor to the lysosomal pathway (CarvajalGonzalez et al., 2014) . As glycine receptor antibodies bind to rodent pontine reticular formation and spinal cord (Turner et al., 2011) , the internalisation may predominantly affect these neurons. In addition, there is evidence for an inflammatory component to this pathology. Indeed, a post-mortem study of a patient with PERM and antibodies to the glycine receptor plus the NMDAR, showed an encephalomyelitis with predominant CD8 T cells in apposition to neurons in the hippocampus and Purkinje cell layer (Turner et al., 2011) . This was similar to previous autopsy reports of PERM which demonstrated an encephalomyelitis, centred predominantly on the limbic grey matter and brainstem with B and T cell infiltrates (Barker et al., 1998) .
Rarer NSAb targets
AMPA-receptor (AMPAR)
Described shortly after NMDAR-antibody encephalitis, AMPARantibody encephalitis remains rare. Small cohorts (H€ oftberger et al., 2015; Lai et al., 2009 ) characterise a condition that often affects older women with tumours in 64%. The syndrome is LE, with a proportion showing additional features including prominent psychiatric manifestations and ataxia.
AMPARs are glutamate-gated ion channels, composed of GluA 1e4 tetrameric subunits. They mediate the fast excitatory neurotransmission in the CNS and are important in learning, memory and plasticity (Henley and Wilkinson, 2013) . Antibodies target the GluA1 or 2 subunits, and both GluA1/2 and GluA2/3 receptors are highly expressed in limbic regions in the brain (Lai et al., 2009 ). Patient's antibodies affect AMPAR synaptic localisation, mediated currents and the relative contributions of excitatory and inhibitory neuronal functions (Lai et al., 2009; Peng et al., 2015) .
DPPX potassium channel (dipeptidyl-peptidase-like protein 6)
DPPX-antibodies have been reported in few patients to date who present with an encephalitis associated with diarrhoea and weight loss, seizures, tremor and myoclonus (Boronat et al., 2013; Piepgras et al., 2015) . Brainstem features, including rigidity and central hyperexcitability, are also described, and a few patients have a syndrome consistent with PERM Tobin et al., 2014) .
DPPX is a regulatory subunit of the Kv4.2 potassium channel complex expressed in neuronal dendrites and soma, and associates with the channels' pore-forming subunits (Kim et al., 2008) . Kv4.2 is responsible for transient, inhibitory currents in the central and peripheral nervous system and is involved in the generation of cardiac and gastrointestinal rhythms (Niwa and Nerbonne, 2010; Piepgras et al., 2015) . DPPX antibodies decrease membrane expression of DPPX and Kv4.1 in hippocampal neurons and cause hyperexcitability of enteric neurons (Piepgras et al., 2015) , a possible explanation for the initial severe diarrhoea frequently seen in patients with this condition. Consistent with this, DPPX knockout mice show enhanced neuronal excitability (Sun et al., 2011) , and antibody-mediated downregulation of DPPX and Kv4.1 may explain the central hyperexcitabilty reported in this rare syndrome.
Treatment
Current first and second line treatment
In addition to supportive therapies, first-line treatment of these disorders is usually a combination of steroids with either plasma exchange or IVIG or both. Second-line treatments include cyclophosphamide and rituximab (Titulaer et al., 2013) . Tailoring of these treatments between conditions is required. For instance, patients diagnosed early enough with FBDS and LGI1-antibodies are usually corticosteroid-responsive and often achieve good outcomes without second-line therapies . By contrast, in patients with NMDAR-antibody encephalitis (Titulaer et al., 2013) , only around 50% respond to first-line treatment and the remaining 50% require second-line treatment to achieve a similar outcome. Overall, around 50% have no disability at 24 months. However, retrospective observational studies highlight intrinsic limitations. For example, the patients with excellent rapid outcomes often underwent limited follow-up, and patients who were diagnosed at the time of discovery of this disease would not have been recognised or treated early. Nevertheless, immunotherapies have decreased relapse rates to 5e10% and early treatment was associated with a higher chance of improved outcomes (Titulaer et al., 2013) , something that has been mirrored in a small prospective cohort of patients with LGI1-antibody encephalitis (Irani et al., 2013) .
Evidence for rituximab is less convincing in LGI1-antibody encephalitis but current evidence is confined to very small sample sizes (Irani et al., 2014b) . Relapse rates in LGI1 or CASPR2-antibody encephalitis remain controversial and estimates vary from 5% to 20% van Sonderen et al., 2016) . Likely reasons for this include differing intensities or duration of immunotherapies, and relative lags to recognition and treatment.
In other antibody-mediated diseases, largely because of their rarity, there is a less clear idea of treatment responses. However, in general, around 70% of patients respond to immunotherapies and factors associated with poorer outcomes include co-existent tumours, delay to treatment, and poor initial functional status. This explains the higher mortality seen in association with antibodies which more often occur with tumours such as GABA A -, GABA B -, and AMPA-receptor antibodies (Varley et al., 2014 ).
Next-generation, immunotherapies
More specific, targeted therapies are an attractive prospect as most current immunosuppressive therapies have a wide range of off-target side-effects which contribute significantly to morbidity (Irani et al., 2013) . Various methods have been employed to target the presumed pathogenic entities in these diseases, and are discussed below.
Antibody effector mechanism inhibition
As previously discussed, there is good evidence for the contribution of complement deposition to pathogenicity in NMO. Therefore, eculizumab, a therapeutic humanised monoclonal antibody that neutralises the complement protein C5, has been trialled. Eculizumab prevents the generation of C5a, and the proinflammatory and cytolytic effects of terminal complement activation (Rother et al., 2007 ). An open label pilot study in 14 patients with active NMO (two attacks in 6 months, or 3 in 12 months), showed significant reduction of attack frequency with eculizumab . A randomised controlled trial is currently recruiting.
Antibody level reduction
Plasma-exchange and immunoabsorption reduce circulating IgG levels. A retrospective study showed that 86% of patients with NSAbs improved after immunoabsorption, whereas patients with antibodies to intracellular antigens did not improve (Dogan Onugoren et al., 2016) . Most striking was the amount of antibody clearance achieved: NSAb titres decreased by 97% (serum) and 64% (CSF) four days after immunoabsorption, and this fell further to 98% (serum) and 88% (CSF) at four weeks. However, the relative efficacy of plasma exchange/immunoabsorption compared to corticosteroids or intravenous immunoglobulins is yet to be studied.
B cell inhibition
B cells interact directly with antigen and are crucial to the propagation and maturation of the immune response, not least their potential to differentiate into plasma cells e the major antibody producing cell in the humoral immune response. Indeed, IL-6 is a cytokine which aids the development of B-cells into mature, antibody-secreting cells (Cassese et al., 2003) , as shown in a study from AQP4-antibody positive patients (Chihara et al., 2011) . Concordantly, preliminary data using an anti-IL-6 monoclonal, tocilizumab, are encouraging in both NMO and autoimmune encephalitis Ringelstein et al., 2015) . More work must be done to assess the efficacy of tocilizumab as a stand-alone agent. Also, low dose IL-2 has been used to stimulate T-regulatory cells and therefore attenuate B cell responses, with similar encouraging results . The major inevitable caveat with these studies is that several immunotherapy interventions are often simultaneously escalated, making it difficult to accurately attribute effects to any single agent.
Plasma cell targeted approach
As plasma cells are key antibody producers, it seems logical to target them in these conditions. Plasma cells often lose expression of CD19, CD20 and lack many other surface markers, meaning they are a more elusive target for traditional biologics. Bortezomib is a drug originally designed to treat myeloma and mantle cell lymphoma (Piperdi et al., 2011) . Bortezomib exerts its effect by inhibiting proteasome function, and as plasma cells produce vast quantities of protein, they are particularly dependent on proteasomal function. Hence, bortezomib may selectively eliminate plasma cells. Indeed, bortezomib has been trialled as a treatment in a small number of NMDAR-AbE patients with promising initial results (Behrendt et al., 2016; Scheibe et al., 2016) .
Conclusions
NSAb-mediated diseases are a diverse group of disorders in terms of antigenic targets, clinical phenotypes, pathogenesis of antibodies, associations with cancers, and treatment responses. Discovery of new targets is ongoing but appears to be detecting rare syndromes in recent years, suggesting perhaps alterative research approaches are now required. Optimal treatments are increasingly understood but there is a lack of controlled, prospective treatment data and this must be a priority for the field. New treatment avenues must also be explored and a variety of approaches are required to evaluate the relative efficacy of several logical potential options. A neuroscience-based approach to the dysfunction of channels caused by these diseases is important and is exemplified by the work in NMDAR-antibody encephalitis. As important, however, is study of the immunology of these diseases as a window into targeted, personalised medicine attacking the populations of cells which generate the pathogenic antibodies. By using a combination of approaches, while simultaneously improving clinical recognition to achieve earlier treatments, outcomes for patients with these conditions should be enhanced over the next few years.
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